Taitel Haya
Known title: DirectorCIK: 0001979599
Taitel Haya's purchase track record
How the stock did after each of Taitel Haya's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 22, 2023
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+106.9%
3 months: +7.3%
Beat the S&P 500
100%
median +95.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2026 | ENTX | $11K | -13.8% | +106.9% | +11.3% |
| 1/10/2024 | ENTX | $15K | +178.8% | +125.0% | +17.8% |
| 8/22/2023 | ENTX | $11K | +7.3% | +54.4% | +13.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ENTX | ▲ Buy | Grant | 20,790 | $0 | 8/7/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 7,500 | $11K | 2/10/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 26,329 | $0 | 1/1/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 6,922 | $0 | 1/15/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 7,278 | $0 | 10/2/2024 | View on chart |
| ENTX | ▲ Buy | Grant | 15,335 | $0 | 8/27/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 9,500 | $9K | 1/12/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 7,615 | $6K | 1/10/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 18,000 | $11K | 8/22/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.